GeneDx Holdings Corp vs Consumer Staples Select Sector SPDR Fund — how do they compare? GeneDx Holdings Corp trades at $86.53 (market cap $2.58B), while Consumer Staples Select Sector SPDR Fund trades at $83.3. The key difference: Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| WGS | XLP | |
|---|---|---|
Market Cap | $2.58B | — |
Sector | Technology | — |
52-Week High | $167.51 | $90.00 |
52-Week Low | $34.51 | $75.61 |
Enterprise Value | $2.61B | — |
Signals from Pluang's Aura AI — not financial advice
WGS trades at $85.87, down 0.14% on the day, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4 million, beating estimates, and achieved adjusted profitability ahead of schedule. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics, driving positive sentiment.
Outlook is cautiously optimistic due to strong analyst support (90.9% buy ratings) and revenue growth, but risks include negative net income margins, high valuation multiples, and ongoing class action lawsuits. The stock's upside potential hinges on sustained operational improvements and market expansion in genomics diagnostics.
XLP trades at $84.02, down 0.66% amid broader market volatility. The technical picture shows bearish momentum with key support at $83 and resistance at $85. Analyst sentiment remains strongly positive with 100% buy ratings, while recent news highlights XLP's defensive positioning during economic uncertainty as consumer spending shows signs of moderation.
XLP offers defensive exposure with strong institutional support, though technical weakness and economic headwinds create near-term pressure. The ETF's low expense ratio and dividend yield provide stability, but sector rotation risks and consumer spending trends warrant monitoring for sustained performance.
Trailing returns across standard periods
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →